TRK-380, a Novel Selective Human β3-Adrenoceptor Agonist, Ameliorates Formalin-induced Pollakiuria in Rats and Carbachol-induced Bladder Contraction in Dogs

Kanie, Sayoko; Otsuka, Atsushi; Kobayashi, Ryosuke; Itaba, Shoichi; Yokokawa, Hiroshi; Tajima, Yoriko; Ozono, Seiichiro; Hayashi, Ryoji; Mochizuki, Hidenori

doi:10.1016/j.urology.2013.07.016

Cited by 6 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the first experiment, 80 mM KCl was added to contract the strips. After the contractions reached plateau, responses to vehicle (time control), isoproterenol (a non‐selective β‐AR agonist), dobutamine (a selective β 1 ‐AR agonist), procaterol (a selective β 2 ‐AR agonist), and TRK‐380 (a selective β 3 ‐AR agonist) were added, with drug concentration increasing at 10 min intervals (10 −10 –10 −4 M). After cumulative administration of each agent, 10 μM forskolin (FK) was added to each organ bath to effect relaxation.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The expression of β₃-adrenoceptors and their function in the human prostate

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

“…TTX was purchased from Wako Ltd. (Osaka, Japan). TRK‐380 was synthesized and provided by Toray Industries Inc. (Kanagawa, Japan). FK was dissolved in dimethyl sulfoxide, and procaterol was dissolved in ethanol.…”

Section: Methodsmentioning

confidence: 99%

The expression of β₃-adrenoceptors and their function in the human prostate

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…There have been many early investigations of other novel and putative β 3 -AR agonists for management of OAB, including CL-316243 [ 28 ], aryloxypropanolamine [ 29 ], conformationally restricted acetanilides [ 30 ], TRK-380 [ 31 ], AJ-9677 [ 32 ], and BRL37344 [ 33 ]. These agents have been reported as being in development, but no clinical data have been published.…”

Section: Oab Drugs In the Pipelinementioning

confidence: 99%

Drug therapy of overactive bladder - What is coming next?

Andersson

2015

Korean J Urol

View full text Add to dashboard Cite

After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy versus the previous gold standard, antimuscarinics. However, since these agents also have limitations there has been increasing interest in what is coming next - what is in the pipeline? Despite progress in our knowledge of different factors involved in both peripheral and central modulation of lower urinary tract dysfunction, there are few innovations in the pipe-line. Most developments concern modifications of existing principles (antimuscarinics, β3-receptor agonists, botulinum toxin A). However, there are several new and old targets/drugs of potential interest for further development, such as the purinergic and cannabinoid systems and the different members of the transient receptor potential channel family. However, even if there seems to be good rationale for further development of these principles, further exploration of their involvement in lower urinary tract function/dysfunction is necessary.

show abstract

“…Sodium pentobarbital, a short-acting GABA A -receptor potentiator [11], is a reliable anesthetic for survival experiments, which is often used in urodynamic studies [4,9,[12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28]. However, pentobarbital can abolish the micturition in some cases [12,29,30].…”

Section: Introductionmentioning

confidence: 99%

Verification and Defined Dosage of Sodium Pentobarbital for a Urodynamic Study in the Possibility of Survival Experiments in Female Rat

Abulikim

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objectives. To evaluate the effects of pentobarbital dosages on lower urinary tract function and to define an appropriate dosage of sodium pentobarbital that would be suitable for urodynamic studies in which recovery from anesthesia and long term survive were needed for subsequent experiment. Methods. Twenty-four 8-week-old, female, virgin, Sprague-Dawley rats (200-250 g) were used in this study. Rats in study groups received gradient doses of pentobarbital intraperitoneally, and those in the control group received urethane intraperitoneally. External urethral sphincter electromyography (EUS-EMG) was recorded simultaneously during cystometry and leak point pressure tests. The toe-pinch reflex was used to determine the level of anesthesia. Results. Micturition was normally induced in both the urethane group and 32 mg/kg pentobarbital group. However, in groups of 40 mg/kg or 36 mg/kg pentobarbital, micturition failed to be induced; instead, nonvoiding contractions accompanied by EUS-EMG tonic activity were observed. There were no significant differences in leak point pressure or EUS-EMG amplitude or frequency between the urethane and 32 mg/kg pentobarbital groups. Conclusions. This study confirmed significant dose-dependent effects of pentobarbital on lower urinary tract function and 32 mg/kg pentobarbital as an appropriate dosage for recovery urodynamic testing, which enable the achievement of expected essential micturition under satisfactory anesthesia in female rats.

show abstract

TRK-380, a Novel Selective Human β3-Adrenoceptor Agonist, Ameliorates Formalin-induced Pollakiuria in Rats and Carbachol-induced Bladder Contraction in Dogs

Cited by 6 publications

References 30 publications

The expression of β₃-adrenoceptors and their function in the human prostate

The expression of β₃-adrenoceptors and their function in the human prostate

Drug therapy of overactive bladder - What is coming next?

Verification and Defined Dosage of Sodium Pentobarbital for a Urodynamic Study in the Possibility of Survival Experiments in Female Rat

Contact Info

Product

Resources

About

TRK-380, a Novel Selective Human β3-Adrenoceptor Agonist, Ameliorates Formalin-induced Pollakiuria in Rats and Carbachol-induced Bladder Contraction in Dogs

Cited by 6 publications

References 30 publications

The expression of β3-adrenoceptors and their function in the human prostate

The expression of β3-adrenoceptors and their function in the human prostate

Drug therapy of overactive bladder - What is coming next?

Verification and Defined Dosage of Sodium Pentobarbital for a Urodynamic Study in the Possibility of Survival Experiments in Female Rat

Contact Info

Product

Resources

About

The expression of β₃-adrenoceptors and their function in the human prostate

The expression of β₃-adrenoceptors and their function in the human prostate